200,000+ products from a single source!
sales@angenechem.com
Home > Pyridines > 162542-90-7
162542-90-7 | Pyridine, 4-[(2R)-2-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-phenylethyl]-
CAS No: 162542-90-7 Catalog No: AG001T8P MDL No:
Product Description
Catalog Number:
AG001T8P
Chemical Name:
Pyridine, 4-[(2R)-2-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-phenylethyl]-
CAS Number:
162542-90-7
Molecular Formula:
C25H27NO2
Molecular Weight:
373.4874
IUPAC Name:
4-[(2R)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine
InChI:
InChI=1S/C25H27NO2/c1-27-24-12-11-21(18-25(24)28-22-9-5-6-10-22)23(20-7-3-2-4-8-20)17-19-13-15-26-16-14-19/h2-4,7-8,11-16,18,22-23H,5-6,9-10,17H2,1H3/t23-/m1/s1
InChI Key:
UTUUPXBCDMQYRR-HSZRJFAPSA-N
SMILES:
COc1ccc(cc1OC1CCCC1)[C@@H](c1ccccc1)Cc1ccncc1
Properties
Complexity:
438
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
1
Defined Bond Stereocenter Count:
0
Exact Mass:
373.204g/mol
Formal Charge:
0
Heavy Atom Count:
28
Hydrogen Bond Acceptor Count:
3
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
373.496g/mol
Monoisotopic Mass:
373.204g/mol
Rotatable Bond Count:
7
Topological Polar Surface Area:
31.4A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
5.7
Literature
| Title | Journal |
|---|---|
| Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. | Journal of medicinal chemistry 20080925 |
| Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain. | European journal of pharmacology 20071114 |
| Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity. | Journal of medicinal chemistry 20030605 |
| Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors. | Bioorganic & medicinal chemistry letters 20030602 |
| Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: prevention of reactive intermediate formation and covalent binding. | Bioorganic & medicinal chemistry letters 20020819 |
| Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones. | Journal of medicinal chemistry 20020606 |
| Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones. | Journal of medicinal chemistry 20020606 |
| Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor. | Bioorganic & medicinal chemistry letters 20020603 |
| Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects. | British journal of pharmacology 20010701 |
| Investigation of the in vitro metabolism profile of a phosphodiesterase-IV inhibitor, CDP-840: leading to structural optimization. | Drug metabolism and disposition: the biological fate of chemicals 20010301 |
| Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models. | Inflammation 20000801 |
| CDP840: a novel inhibitor of PDE-4. | Cell biochemistry and biophysics 19980101 |
| The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. | The European respiratory journal 19970501 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.